Ali Nosrati Andevari

Dr. Ali Nosrati Andevari


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
AAAli Nosrati Andevari
Ali Nosrati Andevari
SMSoheila Moein
Soheila Moein
DQDurdi Qujeq
Durdi Qujeq
ZMZoleika Moazezi
Zoleika Moazezi
KHKarimollah Hajian-Tilaki
Karimollah Hajian-Tilaki

20 September 2025 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
AAAli Nosrati Andevari
Ali Nosrati Andevari
AFAsghar Heidari Firoozjaee
Asghar Heidari Firoozjaee
NMNeda Meftah
Neda Meftah
HAHadi Arabi Asciabari
Hadi Arabi Asciabari
FBFaegheh Bahri
Faegheh Bahri
DQDurdi Qujeq
Durdi Qujeq

12 August 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
AAAli Nosrati Andevari
Ali Nosrati Andevari
MKMohsen Koolivand
Mohsen Koolivand
Introduction: Type 2 diabetes mellitus (T2DM) is one of the most common metabolic disorders arising from decreased insulin secretion and insulin sensitivity. Patients with T2DM take statins to prevent diabetic complications and mitigate mortality risk associated with this disease. Statins primarily function by blocking HMG‐CoA, resulting in reduced cholesterol levels. Statins have been suggested to possess certain antidiabetic properties. However, the overall effects of statins remain controversial. The aim of this study was to investigate the mechanisms and triggering conditions for the development of statin‐induced T2DM, despite their reported pleiotropic antidiabetic effects. Methods: This paper is a narrative review. A thorough literature search was carried out across PubMed, Scopus and Google Scholar to identify studies relevant to the evaluation. Results: In the cholesterol biosynthesis pathway (the mevalonate pathway), in addition to cholesterol, isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate are also produced. Inhibition of these metabolites largely mediates the diabetogenic action of statins. The effects of statins on insulin secretion appear to be largely independent of cholesterol. However, the inhibition of cholesterol synthesis in pancreatic beta cells reduces insulin secretion through impaired function of SNARE proteins and calcium channels. The most prominent effects of statins on insulin secretion and sensitivity are attributed to the suppression of isoprenoids, particularly Cdc42, Rac1 and Rab. Furthermore, studies have shown that statins directly affect the levels of some insulin‐sensitivity‐related factors, independent of the identification of isoprenoid‐mediated pathways. Conclusions: Atorvastatin, simvastatin and rosuvastatin possess the most pronounced diabetogenic properties. In contrast, lovastatin, fluvastatin, pitavastatin and most notably pravastatin exert either neutral or advantageous effects with respect to glucose metabolism.

18 October 2022 in International Journal of Medical Laboratory
Verified
Journal Article
Closed access
AAAli Nosrati Andevari
Ali Nosrati Andevari
SMSoheila Moein
Soheila Moein
DQDurdi Qujeq
Durdi Qujeq
ZMZoleika Moazezi
Zoleika Moazezi
KHKarimollah Hajian-Tilaki
Karimollah Hajian-Tilaki
Background and Aims: Atorvastatin may alter glycemic traits and lipid profiles. This study aimed to evaluate the effects of atorvastatin on biochemical variables in patients with type 2 diabetes and pre-diabetes (borderline diabetes). Materials and Methods: This study included 80 individuals divided into five groups. Patients with type 2 diabetes mellitus and pre-diabetes used atorvastatin 20 mg/day for three months. After three months, variables such as serum fasting blood glucose (FBS), cholesterol, triglyceride, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and glycosylated hemoglobin (HbA1c) levels were measured to assess the status of diabetes and pre-diabetes condition. Linear regression was applied to determine the association between atorvastatin uses and alters of biochemical variables levels. Results: The serum FBS and HbA1c levels in patients with diabetes and pre-diabetes who use atorvastatin were significantly lower than in patients with diabetes and pre-diabetes who did not use atorvastatin (p=0.001). Serum cholesterol and LDL-C levels decreased in diabetic and pre-diabetic patients who used atorvastatin in comparison with diabetic and pre-diabetic patients who did not use atorvastatin (p=0.001). In patients with pre-diabetes, the use of atorvastatin slightly increased serum HDL-C levels. However, in patients with diabetes, the use of atorvastatin slightly decreased serum HDL-C level (p= 0.001). Diabetic and pre-diabetic patients who use atorvastatin significantly decreased serum triglyceride levels (p=0.016), while in diabetic and pre-diabetic patients, using atorvastatin slightly increased the serum insulin level (p= 0.003). Conclusions: Atorvastatin using alters fat and sugar indices in diabetic and pre-diabetic patients.